Asia tech stocks slide tracking Wall St losses amid AI doubts, govt. uncertainty
Shareholders of Silexion Therapeutics Corp (NASDAQ:SLXN) approved an amendment to the company’s memorandum of association to increase its authorized share capital, according to a statement released Tuesday based on a filing with the Securities and Exchange Commission.
At an extraordinary general meeting originally held on August 12 and reconvened Tuesday due to a lack of quorum, shareholders voted on a proposal to raise the company’s authorized share capital from $20,000, divided into 1,481,482 ordinary shares with a par value of $0.0135 each, to $121,500, divided into 9,000,000 ordinary shares with the same par value.
The meeting was attended by holders of 1,459,924 ordinary shares, representing about 16.8% of the company’s issued and outstanding ordinary shares. In accordance with company articles, the shareholders present after a half-hour wait constituted a quorum for conducting business.
The proposal received 699,871 votes in favor (59.8% of votes cast, excluding abstentions), 470,828 votes against (40.2%), and 289,225 abstentions. The amendment was approved by a simple majority of shareholders present, satisfying the approval threshold set by the company’s articles of association.
The memorandum amendment was filed with the Registrar of Companies of the Cayman Islands on Tuesday and became effective the same day.
Silexion Therapeutics Corp is incorporated in the Cayman Islands and its ordinary shares and warrants (NASDAQ:SLXNW) are listed on The Nasdaq Stock Market LLC. The information in this article is based on a company statement filed with the SEC.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.